NCT00851552View on ClinicalTrials.gov

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

Given IV

DRUG

bortezomib

Given IV

DRUG

pegylated liposomal doxorubicin hydrochloride

Given IV

GENETIC

gene expression analysis

Correlative Study

GENETIC

polymerase chain reaction

Correlative Study

GENETIC

polymorphism analysis

Correlative Study

GENETIC

proteomic profiling

Correlative Study

OTHER

flow cytometry

Correlative Study

OTHER

laboratory biomarker analysis

Correlative Study

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Ortho Biotech, Inc.
All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT00851552 - Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | Biotech Hunter | Biotech Hunter